Respiro Diagnostics is developing a non-invasive liquid biopsy platform that captures DNA, RNA and proteins from exhaled breath using a proprietary breath collection device combined with laboratory analysis. The company positions its technology as an alternative to invasive tissue biopsies and blood-based liquid biopsies, aiming to support earlier diagnosis and provide molecular profiling to guide treatment decisions. Respiro has completed initial proof-of-concept testing in mesothelioma patients and plans to start its first lung cancer clinical study at Aalborg University Hospital in September 2026. The startup is also evaluating applications of its platform for other respiratory conditions such as pulmonary hypertension and asthma. Respiro is UK-based and was founded by Alison Quinn and Dr Theo Issitt. The company recently raised £1 million in a pre-seed round to fund clinical research and further development of its device and laboratory platform.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026